Kluver-Bucy syndrome

Summary

Kluver-Bucy syndrome (MONDO:0005817) is a disease. A subtype of impulse control disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Kluver-Bucy syndrome
Mondo ID	MONDO:0005817
EFO	EFO:0007335
MeSH	D020232
Orphanet	157823
DOID	DOID:2510
NCIT	C84802
SNOMED CT	10651001
UMLS	C0270707
MedGen	124361
GARD	0006840
MedDRA	10066431
NORD	1338
Is cancer (heuristic)	no

Also known as: bilateral temporal lobe disorder · Kluver Bucy syndrome · KLüver-Bucy syndrome · memory loss, extreme sexual behavior, placidity, and visual distractibility · post-encephalitic Kluver Bucy syndrome (type) · post-traumatic Kluver Bucy syndrome (type) · syndrome, Kluver-Bucy · temporal lobectomy behavior syndrome · temporal lobectomy behaviour syndrome

Disease family

This is a subtype of impulse control disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › impulse control disorder › Kluver-Bucy syndrome

Related subtypes (6): kleptomania, intermittent explosive disorder, pyromania, pathological gambling, trichotillomania, primary polydipsia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.